SCHEMBL487036

SCHEMBL487036

O=S(=O)(c1ccccc1)c1cccc(O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.61
POLB P06746 2/20 0.58
GAA P10253 2/20 0.58
GFER P55789 1/20 0.58
CA2 P00918 2/20 0.56
HSD17B1 P14061 2/20 0.51
HSD17B2 P37059 2/20 0.51
ABCC9 O60706 1/20 0.49
ABCC8 Q09428 1/20 0.49
KCNJ11 Q14654 1/20 0.49
KCNJ8 Q15842 1/20 0.49
LMNA P02545 3/20 0.49
ALDH1A1 P00352 3/20 0.49
THRB P10828 1/20 0.49
TSHR P16473 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MMP2 P08253 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10340796 0.93 CA2 (0.61) HTR6POLBGAAGFERCA2
SCHEMBL31146723 0.93 CA2 (0.61) HTR6POLBGAAGFERCA2
SCHEMBL69135 0.93 CA2 (0.61) HTR6POLBGAAGFERCA2
Phenol SCHEMBL28246660 0.91 HTR6 (0.61) HTR6POLBGAAGFERCA2
SCHEMBL10587183 0.91 CA2 (0.59) HTR6POLBGAAGFERCA2
SCHEMBL10860256 0.91 CA2 (0.59) HTR6POLBGAAGFERCA2
SCHEMBL1754882 0.89 HSD17B1 (0.56) HTR6POLBGAAGFERCA2
(Phenylsulfonyl)Benzene SCHEMBL10795426 0.86 HTR6 (0.74) HTR6POLBGAAGFERCA2
(Phenylsulfonyl)Benzene SCHEMBL28171322 0.86 HTR6 (0.74) HTR6POLBGAAGFERCA2
SCHEMBL18503833 0.84 HTR6 (0.64) HTR6POLBGAAGFERCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212614-B1 PROCESS FOR MAKING BENZOXAZINES CYTEC IND INC (US) 2019-05-01 EP disclosed
CN-102391203-A Intermediate of 6-substituted-1-methyl-1-h-benzimidazole derivative and method for producing same SANKYO CO 2012-03-28 CN disclosed
US-8106079-B2 Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same SANKYO COMPANY, LIMITED (JP) 2012-01-31 US disclosed
CN-101068770-B Process for producing 6-substituted-1-methyl-1-H-benzimidazole derivative and synthetic intermediate therefor SANKYO CO 2012-01-04 CN disclosed
US-7816552-B2 Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same SANKYO COMPANY, LIMITED (JP) 2010-10-19 US disclosed
US-20100234612-A1 Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same SANKYO COMPANY, LIMITED (JP) 2010-09-16 US disclosed
US-20090023929-A1 Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same SANKYO COMPANY, LIMITED (JP) 2009-01-22 US disclosed
CN-101068770-A Process for producing 6-substituted-1-methyl-1-H-benzimidazole derivative and synthetic intermediate therefor SANKYO CO (JP) 2007-11-07 CN disclosed
EP-1798216-A1 INTERMEDIATE OF 6-SUBSTITUTED-1-METHYL-1-H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR PRODUCING SAME Sankyo Company, Limited (JP) 2007-06-20 EP disclosed
US-5468857-A Phenylmethoxypropenoic esters IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-11-21 US disclosed
EP-0307103-B1 Fungicides ZENECA LTD (GB) 1994-09-21 EP disclosed
US-5334748-A A methyl 2-aryl heterofunctional phenoxyphenyl-3-methoxy-propenoate compound; treating the plant diseases IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-08-02 US disclosed
EP-0307103-A2 Fungicides ZENECA LIMITED (GB) 1989-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023929-A1 Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same AZI2, CYC1, CCNI HTR6 504/4885POLB 182/4885GAA 4200/4885
US-20100234612-A1 Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same CYC1, CYP2B6, COX6B1 HTR6 358/4885POLB 415/4885GAA 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.